Sponsored Links
| Synta Announces Ganetespib Phase 2 Non-Small Cell Lung Cancer Trial Results Show Encouraging Single Agent Clinical Activity |
 |
 |
 |
| Medical News - Lung Cancer | |||
|
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease... Read more: Lung Cancer News From Medical News Today
|